Stereotaxis (STXS)
(Delayed Data from AMEX)
$2.10 USD
+0.01 (0.48%)
Updated May 17, 2024 03:59 PM ET
After-Market: $2.10 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
STXS 2.10 +0.01(0.48%)
Will STXS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for STXS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STXS
Stereotaxis (STXS) Inks Deal to Buy Access Point Technologies
Stereotaxis (STXS) Seeks Clearance for MAGiC Catheter
STXS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alphatec (ATEC) Reports Q4 Loss, Tops Revenue Estimates
Penumbra (PEN) Q4 Earnings Beat Estimates
AxoGen (AXGN) Moves 6.8% Higher: Will This Strength Last?
Other News for STXS
Stereotaxis Invited by Africa Heart Rhythm Association to Present its Innovative Robotic Solution to Expand High-Quality Therapy in Underserved Regions of Africa
Stereotaxis to present at HRS Africa Summit 2024
Analysts Are Bullish on Top Healthcare Stocks: Stereotaxis (STXS), Jasper Therapeutics (JSPR)
Analysts’ Top Healthcare Picks: Stereotaxis (STXS), Capricor Therapeutics (CAPR)
Stereotaxis Inc (STXS) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth and Challenges